![](https://abc17news.b-cdn.net/abc17news.com/2021/06/kmiz-health-375x225.png)
A new $16,000 postpartum depression drug is here. How will insurers handle it?
By April Dembosky, KQED and KFF Health News (KQED/KFF Health News) — A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness. But most private health insurers have yet to publish criteria for when they will cover it, according to a new analysis of insurance
Continue Reading